In recent years, Estonia has witnessed a notable increase in the diagnoses of attention deficit hyperactivity disorder (ADHD) alongside a simultaneous surge in the use of prescription psychostimulants such as lisdexamfetamine. This medication, often framed as a medical breakthrough, is said to help individuals manage their symptoms by improving focus and reducing fatigue. However, this positive narrative overlooks a critical aspect: lisdexamfetamine is a form of amphetamine, which carries significant risks of misuse and adverse psychological effects.

The article emphasizes the dual nature of lisdexamfetamine, which, while beneficial for many individuals, can potentially lead to severe side effects such as psychosis. Eero Vasar, an academic and physiology professor at the University of Tartu, highlights that society is involuntarily participating in a large-scale experiment with these stimulant medications, the long-term consequences of which remain to be seen. This normalization of amphetamines for treating attention disorders raises critical ethical and health questions about dependency and the implications for future generations.

As discussions around the medical use of amphetamines gain traction, it is crucial for stakeholders, including healthcare professionals, policymakers, and the public, to weigh the benefits against the risks. As more individuals are prescribed these drugs, the need for responsible management, comprehensive research, and societal discourse on the implications of such treatments becomes ever more pressing.